

THE PATENT OFFICE IS HEREBY REQUESTED TO ACKNOWLEDGE RECEIPT
OF THE FOLLOWING DOCUMENTS BY DATE STAMPING AND RETURNING
THIS POST CARD

Serial No: 08/182,183

Applicant: Lin et al.

Filed: May 23, 1994

Examiner: Robert C. Hayes, Ph.D.

Art Unit: 1644

Title: Glial Cell Line-Derived Neurotrophic Factor

2 pgs Status Inquiry

S-225E
DRC/khh

Via First Class Mail

March 29, 2001



Amgen Inc.
One Amgen Center Drive
Thousand Oaks, CA 91320-1799

AMGEN

Assistant Commissioner for Patents
Washington, D.C. 20231

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Lin, *et al.*

Group Art Unit: 1644

Serial No.: 08/182,183

Examiner: Robert C. Hayes

Filed: May 23, 1994

Docket No.: SYNE-225-E

For: GLIAL CELL LINE-DERIVED
NEUROTROPHIC FACTOR

Date: March 29, 2001

STATUS LETTER

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In the Office Action dated June 15, 1999 (Paper No. 44) a shortened statutory period for response was set, ending September 15, 1999. The response was filed on July 9, 1999 within one (1) month of the Office Action. Our next document from the Patent Office was the Advisory Action of May 5, 2000. In a telephone conversation with the Examiner, the Examiner stated that prosecution of this case would be reopened to address the issues identified in the Advisory Action.

On August 15, 2000, Applicants filed an amendment and terminal disclaimer to address these last remaining issues identified by the Examiner. In a subsequent telephone conversation, the Examiner suggested that Applicants provide an additional draft discussion amendment for review by the Patent Office. That draft was sent for discussion on October 10, 2000.

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231, on the date appearing below.

March 29, 2001

Date

Signature

Applicants have received no further communication from the Patent and Trademark Office regarding this application. It would be appreciated if the Office would advise applicant(s) of the current status of this application.

Respectfully submitted,



Daniel R. Curry
Attorney for Applicants
Registration No: 32,727
Phone: (805) 447-8102
Date: March 29, 2001

Please send all future correspondence to:

U.S. Patent Operations/DRC
Dept. 4300 M/S 27-4-A
AMGEN INC.
One Amgen Center Drive
Thousand Oaks, California 91320-1799